Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase I/IIa study of melflufen plus dexamethasone in relapsed or relapsed-refractory multiple myeloma
2012-004315-31Phase 2Completed
- Sponsor
- Oncopeptides AB
- Start
- Feb 2013
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan flufenamide in multiple myeloma (MM), sponsored by Oncopeptides AB. Started Feb 2013; status: completed.
02
Drugs
melphalan flufenamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2012-004315-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004315-31.